Keyword: FluGen

FluGen said its intranasal, "universal" flu vaccine helped protect trial participants against a "highly mismatched" strain.

Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.

Here is some other vaccine news of note for the week.

Here is some other vaccine news of note for the week.

If its universal flu vaccine succeeds in phase 3, BiondVax aims to hustle to the European market, CEO Ron Babecoff said.

Here's some other vaccine news of note for the week.

Researchers in England are kicking off the world's first large human trial of a "universal" influenza shot.

Here's other vaccine news of note for this week.

BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.

Nearly a year after raising $12 million to advance its universal flu vaccine candidate into human trials, Madison, WI’s FluGen is heading to the clinic. The company has kicked off a Phase I trial of RedeeFlu, it said in a statement, hoping to take on the challenge of drifted or mismatched flu strains.